RxDoctor Payments Data

Timothy Iliff, MD

Internal Medicine · Daphne, ALNPI 1770564395

Payments from drug & device makers

$362in general payments, 2019–2025

Across 13 payments — averaging $27.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$176
  • Neurocrine Biosciences, Inc.$59
  • Lilly USA, LLC$50
  • Avanir Pharmaceuticals, Inc.$31
  • Otsuka America Pharmaceutical, Inc.$25
  • Acadia Pharmaceuticals Inc$21

What the payments were for

  • Food & beverage$362100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$362 in reported general payments places this provider in the 45th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$111,616
Medicare patients
428
Services billed
1,098

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate85$195,085
EliquisApixaban834$181,254
RexultiBrexpiprazole397$135,820
TrulicityDulaglutide115$103,604
IngrezzaValbenazine Tosylate38$96,945
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$50,237
NuedextaDextromethorphan Hbr/Quinidine61$35,543
MyrbetriqMirabegron120$32,405
EntrestoSacubitril/Valsartan120$29,530
Daptomycin38$24,998
XifaxanRifaximin20$24,754
AustedoDeutetrabenazine15$23,885
TradjentaLinagliptin114$19,605
Atorvastatin Calcium2,033$19,291
Memantine Hcl1,033$18,609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$21$195,08585 claims
Otsuka America Pharmaceutical, Inc.Rexulti$25$135,820397 claims
Lilly USA, LLCTrulicity, Olanzapine$50$117,765855 claims
Neurocrine Biosciences, Inc.Ingrezza$59$96,94538 claims
Avanir Pharmaceuticals, Inc.Nuedexta$31$35,54361 claims
AstraZenecaLokelma$176$16,77926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Daphne

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →